AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
Total Raised
$430M
AEON BiopharmaOllin Biosciences
Last ValuationNot disclosed
Biotech
Sector
Biotech
2013
Founded
2023
Irvine, California
HQ
Chicago, Illinois
Public (AEON)
Status
Private
AEON Biopharma investors
No investors on record.
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Ollin Biosciences.